TriCelX Press Releases - EIN Presswire - Press Release Distribution Service

Published on August 25, 2026 - 20:38 GMT

TriCelX Takes On ALS — Its Third Clinical Program, and the Hardest

FRISCO, TX, UNITED STATES, August 25, 2026 /⁨EINPresswire.com⁩/ -- TriCelX Takes On ALS — Its Third Clinical Program, and the Hardest With today's filing, TriCelX has three clinical programs running on one product — knee osteoarthritis, CTE, and now …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on June 15, 2026 - 09:00 GMT

FDA Clears First-in-Indication Cell Therapy Trial for Chronic Traumatic Encephalopathy — for the Warriors Who Carry CTE

FDA Authorizes TriCelX’s XytriX™ to Enter the Clinic in CTE—the First Cell Therapy Ever Studied in a Disease That Has Devastated Navy SEALs & NFL Players Alike FRISCO, TX, UNITED STATES, June 15, 2026 /⁨EINPresswire.com⁩/ -- TriCelX, Inc. today …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on June 4, 2026 - 13:43 GMT

TriCelX, ADCAN Pharma & DAS Holding Execute Tripartite MOU & Form UAE Joint Venture TriCelX Biotherapeutic Portfolio

FRISCO, TX, UNITED STATES, June 4, 2026 /⁨EINPresswire.com⁩/ -- TriCelX Arabia, LLC — A Phased GCC Distribution and Abu Dhabi Manufacturing Platform Built on TriCelX’s FDA Trial-May-Proceed Clearance for XytriX in Knee Osteoarthritis, the First-of-Kind …

Distribution channels: Business & Economy, International Organizations ...

Published on May 26, 2026 - 09:30 GMT

TriCelX Launches XytriX™ as Department of Defense Collaboration Under the Blast Overpressure Safety Act

Files First Cell Therapy IND in Chronic Traumatic Encephalopathy with Concurrent RMAT and Breakthrough Therapy Designation Requests FRISCO, TX, UNITED STATES, May 26, 2026 /⁨EINPresswire.com⁩/ -- TriCelX, Inc., a vertically integrated clinical-stage …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on May 18, 2026 - 10:30 GMT

TriCelX Files FDA IND for XytriX™ in Chronic Traumatic Encephalopathy (CTE)

XytriX™ Becomes First CTE Biotherapeutic to Reach FDA Under the Blast Overpressure Safety Act FRISCO, TX, UNITED STATES, May 18, 2026 /⁨EINPresswire.com⁩/ -- TriCelX, Inc. (“TriCelX”), a translational leader in evidence-based biotherapeutics, has …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on April 23, 2026 - 09:00 GMT

TriCelX Receives FDA Study May Proceed Letter for XytriX™

The FDA has issued a Study May Proceed letter for TriCelX's Phase 1/2 IND application for XytriX™, authorizing the commencement of the clinical trial. FRISCO, TX, UNITED STATES, April 23, 2026 /⁨EINPresswire.com⁩/ -- TriCelX, Inc. (“TriCelX”), a …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on March 30, 2026 - 09:00 GMT

TriCelX Files IND with FDA & Concurrently Requests RMAT Designation for XytriX™ in the Treatment of Knee Osteoarthritis

IND Filing and Concurrent RMAT Request Position XytriX™ as a Potential Breakthrough Biotherapeutic for More Than 500 Million People Living with Osteoarthritis THE STAR, FRISCO, TX, UNITED STATES, March 30, 2026 /⁨EINPresswire.com⁩/ -- RMAT DESIGNATION …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on October 22, 2025 - 13:00 GMT

TriCelX, Inc. Announces Opening of TriCelX Utah at the University of Utah Research Park

TriCelX, a global translational leader in evidence-based biologics, announced the opening of its TriCelX Utah location at the University of Utah Research Park. FRISCO, TX, UNITED STATES, October 22, 2025 /⁨EINPresswire.com⁩/ -- TriCelX, Inc. (" …

Distribution channels: Business & Economy, Companies ...